

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our directors and/or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development.



CStone Pharmaceuticals

基石藥業

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2616)

**VOLUNTARY ANNOUNCEMENT
FURTHER INCREASE IN SHAREHOLDING BY CEO AND EXECUTIVE
DIRECTOR DR. JIANXIN YANG BY 3,345,000 SHARES,
WITH ACCUMULATED PURCHASE TOTTALLING 7,529,500 SHARES**

This announcement is made by CStone Pharmaceuticals (the “**Company**” or “**CStone**” and together with its subsidiaries, the “**Group**”) on a voluntary basis to inform its shareholders and potential investors in relation to the increase in shareholding in the Company (the “**Shares**”) by Dr. Jianxin Yang (“**Dr. Yang**”), the chief executive officer (the “**CEO**”), president of research and development and an executive director of the Company. Reference is made to the announcement of the Company dated October 3, 2023 in relation to the intention of Dr. Yang to increase shareholding in the Company.

The Company was informed by Dr. Yang that he has purchased a total of 3,345,000 Shares in the open market with his own funds during the period of approximately six months prior to the date of this announcement (the “**Share Purchases**”). Since Dr. Yang assumed the role as the CEO in August 2022, he has purchased a total of 7,529,500 shares in the open market with a price range of HKD 0.82 to HKD 4.60. Following the Share Purchases, Dr. Yang’s total shareholding interest in the Company was approximately 4.97% of the total issued share capital of the Company as at the date of this announcement.

Dr. Yang informed the Company that he is confident with the Company’s outlook, and the increase in his shareholding in the Company represents his belief in the Company’s ability to maintain steady operations and to achieve rapid growth in a complex and volatile market environment, and the Share Purchases demonstrates his unfailing support towards the growth and development of the Company. Dr. Yang does not rule out the possibility of further increasing his shareholding in the Company as and when appropriate.

The board of directors of the Company (the “**Board**”) is of the view that the increase in shareholding of the Company by its CEO, president of research and development and executive director signifies Dr. Yang’s long-term commitment to, and confidence towards, the future business prospects of the Company.

About CStone

CStone (HKEX: 2616) is a biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 12 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Since inception, CStone has obtained 14 NDA approvals for various drugs (including ivosidenib). Multiple late-stage drug candidates are now under pivotal clinical trials or registration. CStone's vision is to bring innovative oncology therapies to cancer patients worldwide.

For more information about CStone, please visit: www.cstonepharma.com.

By Order of the Board
CStone Pharmaceuticals
Dr. Wei Li
Chairman

Suzhou, the People's Republic of China, April 29, 2024

As at the date of this announcement, the board of Directors comprises Dr. Wei Li as Chairman and non-executive director, Dr. Jianxin Yang as executive director, Mr. Kenneth Walton Hitchner III, Mr. Xianghong Lin and Mr. Edward Hu as non-executive directors, and Dr. Paul Herbert Chew, Mr. Ting Yuk Anthony Wu and Mr. Hongbin Sun as independent non-executive directors.